In primary breast cancer, an analysis of molecular subtypes demonstrated that TP53 mutations were more frequent in HER2+ and TNBC breast cancer than in other subtypes (p<0.05, Figure 2B). This evidence concerns the gene TP53 and breast carcinoma.